The oral diabetes drug canagliflozin (Invokana) is an SGLT2 inhibitor that lowers blood sugar by breaking down glucose and excreting it through the kidneys. In addition to good blood sugar control, canagliflozin (Invokana) is notable for its weight loss effects and low incidence of hypoglycemia, making it a promising treatment. On June 9, 2012, based on the results of two phase III clinical trials, Johnson & Johnson's (JNJ) experimental type 2 diabetes drug canagliflozin was found to be more effective in lowering blood sugar than Merck's Januvia and another older drug, glimepiride. Additionally, canagliflo